Amoytop Biotech Gets China Nod to Test Thrombocythemia Drug

Xiamen Amoytop Biotech (SHA:688278) will conduct clinical trials on Pegbin or pegylated interferon α-2b injection after receiving the approval of China's National Medical Products Administration, acco

MT NewswiresJul 8 04:09 ET

Xiamen Amoytop Biotech (688278.SH): Director Lan Chun plans to reduce a total of no more than 380,000 shares of the company's shareholding.

Xiamen Amoytop Biotech (688278.SH) announced on June 14 that Mr. Lan Chun, a director, plans to reduce his shareholding by no more than 380,000 shares in the company through block trading and bulk trading methods due to personal funding needs. The proportion of the company's total share capital will not exceed 0.093%, and the proportion of the number of shares held by himself before the reduction will not exceed 25%. During the reduction period, the price of the reduction will be determined based on the market price during the implementation period.

Gelonghui FinanceJun 14 06:41 ET

Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

With its stock down 16% over the past three months, it is easy to disregard Xiamen Amoytop Biotech (SHSE:688278). But if you pay close attention, you might gather that its strong financials could me

Simply Wall StJun 12 18:00 ET

Tebao Biotech (688278.SH): Currently, the company's main business products are mainly domestic sales

Gelonghui, May 23丨Tebao Biotech (688278.SH) recently said during a survey reception from institutional investors that currently the company's main business products are mainly domestic sales, accounting for 0.19% of overseas sales revenue in 2023. Some of the company's products have been approved for registration in some overseas countries, and in the future, the company will further expand its international business according to business conditions.

Gelonghui FinanceMay 23 04:03 ET

Tebao Biotech (688278.SH): Currently, the actual clinical use of Pegobin is still dominated by dominant groups

Gelonghui, May 23丨Tebao Biotech (688278.SH) recently said during a survey reception from institutional investors that currently the actual clinical use of Pegbin is still dominated by dominant groups. As multiple clinical cure studies for people infected with different chronic hepatitis B infections advance, it has been further discovered that people in the immune control period also have a high clinical cure rate, and the range of treatment groups will gradually expand as clinical research and scientific research continue to advance.

Gelonghui FinanceMay 23 04:01 ET

Is It Smart To Buy Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) Before It Goes Ex-Dividend?

Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) is about to trade ex-dividend in the next day or so. The ex-dividend date occurs one day before the record date which is the day on which shareholders n

Simply Wall StMay 20 20:01 ET